Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
CABL– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis –
August 7, 2025Earnings
Read more →